J.P. Morgan has published a research report on Gilead Sciences GILD raising the price target.
In the report, J.P. Morgan wrote, "Gilead reported solid 2Q results with non-GAAP EPS of $1.00, ahead of JPMe/cons estimates of $0.99 with total product revenues growing 11% y/y to $2.04B (cons: $1.99B). Going into 2Q, there was a lot of anxiety about the risk of lowered guidance (2011 guidance was unchanged) and further uncertainty from the disbursement and use of ADAP funding from several key states (ADAP funding looks intact in 3Q). Hence, we think that GILD shares will react favorably following 2Q results."
J.P. Morgan rated Gilead Overweight with a price target raised from $45.00 to $50.00. Gilead closed Tuesday at $42.16.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsBiotechnologyGilead SciencesHealth CareJ.P. Morgan
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in